BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38706262)

  • 21. Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
    Liu M; Zhou X; Sun L; Tan S; Liu T; Xiao W; Tang J
    Exp Cell Res; 2022 Jan; 410(2):112935. PubMed ID: 34875218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 24. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
    Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
    He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piwi-Interacting RNAs: A New Class of Regulator in Human Breast Cancer.
    Qian L; Xie H; Zhang L; Zhao Q; Lü J; Yu Z
    Front Oncol; 2021; 11():695077. PubMed ID: 34295823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
    Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
    Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
    Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
    Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
    Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
    J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival.
    Li Y; Wu X; Gao H; Jin JM; Li AX; Kim YS; Pal SK; Nelson RA; Lau CM; Guo C; Mu B; Wang J; Wang F; Wang J; Zhao Y; Chen W; Rossi JJ; Weiss LM; Wu H
    Mol Med; 2015 May; 21(1):381-8. PubMed ID: 25998508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Intergenic Noncoding RNA
    Takeiwa T; Mitobe Y; Ikeda K; Hasegawa K; Horie K; Inoue S
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
    Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
    Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.